newsfilter
← Latest News
GlobeNewswire·

Reunion Neuroscience Inc. Provides 2023 Corporate Update

Company Plans to Report Phase 1 Interim Analysis for RE104 in Q1 2023 and Include Data Differentiating its Safety, Tolerability and Pharmacodynamic Profile from Other Psychedelics in Clinical Development On Track to